Skip to main content

ESTUDIO DE LAS FUNCIONES ESPECIFICAS DE LAS PROTEINAS PARP EN EL STRESS REPLICATIVO INDUCIDO POR ONCOGENES Y SU RELEVANCIA EN CANCER

SAF2017-83565-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies

  • Yélamos López, José
  • Lama, Lucía, 1993-
  • Jimeno, Jaime
  • Ali, Syed O.
Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are enzymes which post-translationally modify proteins through poly(ADP-ribosyl)ation (PARylation)-the transfer of ADP-ribose chains onto amino acid residues-with a resultant modulation of protein function. Many targets of PARP-1/2-dependent PARylation are involved in the DNA damage response and hence, the loss of these proteins disrupts a wide range of biological processes, from DNA repair and epigenetics to telomere and centromere regulation. The central role of these PARPs in DNA metabolism in cancer cells has led to the development of PARP inhibitors as new cancer therapeutics, both as adjuvant treatment potentiating chemo-, radio-, and immuno-therapies and as monotherapy exploiting cancer-specific defects in DNA repair. However, a cancer is not just made up of cancer cells and the tumor microenvironment also includes multiple other cell types, particularly stromal and immune cells. Interactions between these cells-cancerous and non-cancerous-are known to either favor or limit tumorigenesis. In recent years, an important role of PARP-1 and PARP-2 has been demonstrated in different aspects of the immune response, modulating both the innate and adaptive immune system. It is now emerging that PARP-1 and PARP-2 may not only impact cancer cell biology, but also modulate the anti-tumor immune response. Understanding the immunomodulatory roles of PARP-1 and PARP-2 may provide invaluable clues to the rational development of more selective PARP-centered therapies which target both the cancer and its microenvironment., This research was funded by The Fundación Científica de la Asociación Española Contra el Cáncer (AECC), grant number PROYEI6018YÉLA, and the Spanish Ministerio de Economía, Industria y Competitividad, grant number SAF2017-83565-R.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo-Campos, M. A.
  • Lutfi, Nuria
  • Bonnin, S.
  • Martínez, C.
  • Velasco-Hernández, Talia
  • García-Hernández, V.
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, R.
  • Colomo, L.
  • Roué, Gaël
  • Guilbaud, G.
  • Dantzer, Françoise
  • Navarro Medrano, Pilar
  • Murga, Matilde
  • Fernández-Capetillo, Óscar
  • Bigas, A.
  • Menéndez, Pablo
  • Sale; J. E.
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the E¿-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic E¿-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors., The J.Y. laboratory is funded by the Spanish Ministerio de Economía, Industria y Competitividad (grant SAF2017-83565-R), Spanish Ministerio de Ciencia e Innovación (grant PID2020-112526RB-I00), and Fundación Científica de la Asociación Española Contra el Cáncer (grant PROYEI6018YÉLA). Work in the J.E.S. laboratory is supported by a core grant to the Laboratory of Molecular Biology from the Medical Research Council (U105178808). The F.D. laboratory is supported by a Laboratory of Excellence grant (ANR-10-LABX-0034_Medalis) to Strasbourg University, Centre National de la Recherche Scientifique. The P.N. laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness/Instituto de Salud Carlos III–Fondo Europeo de Desarrollo Regional (FEDER; PI17/00199 and PI20/00625) and the Generalitat de Catalunya (2017-SGR-225). The P.M. laboratory acknowledges support from Centres de Recerca de Catalunya/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for core support, the Spanish Ministry of Economy and Competitiveness (grant SAF-2019-108160-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (grant LCF/PR/HR19/52160011), and the German Josep Carreras Leukamie Stiftung. Work at the G.R. and P.M. laboratories are cofinanced by the European Regional Development Fund through the Interreg V-A Spain-France-Andorra Program (project PROTEOblood; grant EFA360/19). The O.F.-C. laboratory is funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTI2018-102204-B-I00; cofinanced with European FEDER funds) and the European Research Council (ERC-617840). T.V.-H. was supported by a Marie Sklodowska Curie fellowship (GA792923). The A.B. laboratory is supported by the Spanish Ministry of Economy and Competitiveness (grant PID2019-104695RB-I00)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies

  • Yélamos López, José
  • Lama, Lucía, 1993-
  • Jimeno, Jaime
  • Ali, Syed O.
Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are enzymes which post-translationally modify proteins through poly(ADP-ribosyl)ation (PARylation)-the transfer of ADP-ribose chains onto amino acid residues-with a resultant modulation of protein function. Many targets of PARP-1/2-dependent PARylation are involved in the DNA damage response and hence, the loss of these proteins disrupts a wide range of biological processes, from DNA repair and epigenetics to telomere and centromere regulation. The central role of these PARPs in DNA metabolism in cancer cells has led to the development of PARP inhibitors as new cancer therapeutics, both as adjuvant treatment potentiating chemo-, radio-, and immuno-therapies and as monotherapy exploiting cancer-specific defects in DNA repair. However, a cancer is not just made up of cancer cells and the tumor microenvironment also includes multiple other cell types, particularly stromal and immune cells. Interactions between these cells-cancerous and non-cancerous-are known to either favor or limit tumorigenesis. In recent years, an important role of PARP-1 and PARP-2 has been demonstrated in different aspects of the immune response, modulating both the innate and adaptive immune system. It is now emerging that PARP-1 and PARP-2 may not only impact cancer cell biology, but also modulate the anti-tumor immune response. Understanding the immunomodulatory roles of PARP-1 and PARP-2 may provide invaluable clues to the rational development of more selective PARP-centered therapies which target both the cancer and its microenvironment., This research was funded by The Fundación Científica de la Asociación Española Contra el Cáncer (AECC), grant number PROYEI6018YÉLA, and the Spanish Ministerio de Economía, Industria y Competitividad, grant number SAF2017-83565-R.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice

  • Galindo Campos, Miguel A.|||0000-0002-0650-8660
  • Lutfi, Nura
  • Bonnin, Sarah|||0000-0001-5159-2518
  • Martínez Cáceres, Carlos|||0000-0003-3307-1326
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • García-Hernández, Violeta|||0000-0003-2328-4360
  • Martín Caballero, Juan
  • Ampurdanés, Coral
  • Gimeno, Ramón|||0000-0002-8758-121X
  • Colomo, Luis|||0000-0001-5236-5085
  • Roué, Gaël|||0000-0003-0245-2257
  • Guilbaud, Guillaume|||0000-0002-4345-6855
  • Dantzer, Françoise
  • Navarro, Pilar|||0000-0003-4314-4584
  • Murga, Matilde|||0000-0002-9766-4481
  • Fernández Capetillo, Oscar|||0000-0002-2690-6885
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Sale, Julian E.
  • Yélamos, José|||0000-0003-1195-1496
Dysregulation of the c-Myc oncogene occurs in a wide variety of hematologic malignancies, and its overexpression has been linked with aggressive tumor progression. Here, we show that poly (ADP-ribose) polymerase 1 (PARP-1) and PARP-2 exert opposing influences on progression of c-Myc-driven B-cell lymphoma. PARP-1 and PARP-2 catalyze the synthesis and transfer of ADP-ribose units onto amino acid residues of acceptor proteins in response to DNA strand breaks, playing a central role in the response to DNA damage. Accordingly, PARP inhibitors have emerged as promising new cancer therapeutics. However, the inhibitors currently available for clinical use are not able to discriminate between individual PARP proteins. We found that genetic deletion of PARP-2 prevents c-Myc-driven B-cell lymphoma, whereas PARP-1 deficiency accelerates lymphomagenesis in the Eμ-Myc mouse model of aggressive B-cell lymphoma. Loss of PARP-2 aggravates replication stress in preleukemic Eμ-Myc B cells, resulting in accumulation of DNA damage and concomitant cell death that restricts the c-Myc-driven expansion of B cells, thereby providing protection against B-cell lymphoma. In contrast, PARP-1 deficiency induces a proinflammatory response and an increase in regulatory T cells, likely contributing to immune escape of B-cell lymphoma, resulting in an acceleration of lymphomagenesis. These findings pinpoint specific functions for PARP-1 and PARP-2 in c-Myc-driven lymphomagenesis with antagonistic consequences that may help inform the design of new PARP-centered therapeutic strategies, with selective PARP-2 inhibition potentially representing a new therapeutic approach for the treatment of c-Myc-driven tumors.